Access cutting-edge stargardt-like macular dystrophy treatment through this clinical trial at a research site in Bethesda. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Bethesda location
Preparing your pre-screening questions…
Access stargardt-like macular dystrophy specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related stargardt-like macular dystrophy treatment provided free
Check if you qualify for this stargardt-like macular dystrophy clinical trial in Bethesda, MD
No-Cost Study Care
Local to Bethesda
Convenient for MD residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
Background: STDG3 is an inherited eye disease. Currently there is no treatment for STDG3. Past studies of STDG3 have largely looked at members of large families at a single time point. Researchers want to learn more about the disease at an individual level. Objective: To understand the natural history of changes in the retina that occur in people with STDG3. Eligibility: People ages 10 and older with STDG3 due to a variant in the ELOVL4 gene. Design: Participants will have 6 visits. First they will have a screening visit, followed by a baseline visit. Then they will have a visit 6 months later. Then they will have a visit 1, 2, and 3 years after the first visit. Visits will last 4 to 8 hours. Visits will include the following: Medical history and physical exam. Complete eye exam. Participants' eye pressure and ability to see letters on a vision chart will be tested. Their pupils will be dilated with eye drops. Pictures will be taken of the retina and the inside of the eye. Questions about participants' family history, especially the presence of eye disease. Visual field test. Participants will be seated in front of a large dome and asked to press a button when they see a light within the dome. Electroretinogram. Participants will sit in the dark with their eyes patched for 30 minutes. Then they will wear special contact lenses and watch flashing lights. Optical coherence tomography. Cross-sectional pictures will be taken of participants' retinas. Fundus autofluorescence. Blue light will be shone into participants eyes to assess the health of the retina....
Sponsor: National Eye Institute (NEI)
Yes, this clinical trial (NCT04591483) has an active research site in Bethesda, MD that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for stargardt-like macular dystrophy treatment options in Bethesda, MD, this clinical trial (NCT04591483) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Bethesda research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stargardt-like macular dystrophy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all stargardt-like macular dystrophy clinical trials near you to find additional studies recruiting in your area.
See all pulmonary hypertension clinical trials recruiting in Bethesda — not just this study.
Browse Pulmonary Hypertension Trials in Bethesda →